Nucl Med Mol Imaging.  2021 Jun;55(3):141-145. 10.1007/s13139-021-00691-w.

Angiogenesis-Targeted 68Ga-DOTA-RGD 2 PET/CT Imaging: a Potential Theranostic Application in the Case of Chondrosarcoma

Affiliations
  • 1Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India
  • 2Department of Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India
  • 3Department of Otolaryngology (Head and Neck Surgery), Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India

Abstract

Chondrosarcoma is a cartilaginous tumor of mesenchymal origin. The histology and grade of the tumor determine the chances of relapse and survival. These tumors usually respond poorly to chemo-radiotherapy in cases of non-resectable and recurrent disease. 18F-FDG PET/CT has been used in evaluation of recurrence. However, these tumors show only mild to moderate FDG avidity due to their lower mitotic activity and large acellular matrix. These tumors are known to have a high degree of angiogenesis, especially in those of higher grade. We present a case of a 53-year-old man with grade II chondrosarcoma of the left femur showing only mild avidity on 18F-FDG PET/CT but showing moderate to intense tracer avidity on 68Ga-DOTA-RGD2PET/CT. This may enable the use of angiogenesis-targeted positron and beta-emitting radiopharmaceuticals as a potentially new theranostic alternative treatment in cases of refractory metastatic chondrosarcoma.

Keyword

Chondrosarcoma; Theranostics; Angiogenesis; Integrin αvβ3; RGD2; PET/CT
Full Text Links
  • NMMI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr